AL-1

AL-1 is an experimental **andrographolide-lipoic acid covalent conjugate** synthesized at Jinan University. It is a single small-molecule derivative that combines the diterpenoid andrographolide scaffold with alpha-lipoic acid. In preclinical studies, AL-1 has shown anti-inflammatory, antioxidant, cytoprotective, metabolic, and neuroprotective activity. In TNBS-induced mouse colitis, orally administered AL-1 reduced disease severity, inflammatory cytokines, neutrophil-associated myeloperoxidase activity, NF-kappa B pathway activation, and cyclooxygenase-2 expression, while increasing peroxisome proliferator-activated receptor gamma expression. AL-1 has not been identified as an approved or clinically tested medicine.

Other names

andrographolide-lipoic acid conjugate